To span the realm of opportunities in biotech is to gaze down an infinite loop of possibilities with no beginning or end—a place seemingly at odds with the environs of more practical-minded finance …
Continue Reading about 288: The Big Year | Jack Callicutt, CFO, Galectin Therapeutics →